Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

SSRI ads questioned

Colin Meek
CMAJ March 14, 2006 174 (6) 754-754-a; DOI: https://doi.org/10.1503/cmaj.051634
Colin Meek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Claims in drug monographs and advertising that selective serotonin reuptake inhibitor (SSRI) antidepressants work by normalizing serotonin levels are not based on scientific evidence and should be prohibited, says a leading US psychiatrist.

„Biological psychiatrists have looked very closely for a serotonin imbalance or dysfunction in patients with depression or obsessive compulsive disorder and, to date, it has been elusive,” says Dr. Wayne Goodman, Chair of the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee. Although an SSRI may work well in an individual, this „doesn't prove that there is an underlying imbalance, defect or dysfunction in the person's serotonin system,” he added.

Goodman was reacting to a recent article (December 2005, PLoS Medicine) about the growing body of medical literature that casts doubt on the „serotonin hypothesis.” Co-author Jonathan Leo, associate professor of anatomy at Lake Erie College of Osteopathic Medicine, says the FDA should prohibit SSRI manufacturers from making these claims.

GlaxoSmith-Kline (GSK), for example, claims (www.paxil.com) that paroxetine (Paxil) can „help restore the balance of serotonin — which helps reduce the symptoms of anxiety and depression.” GSK officials refused to comment.

In 2003, Ireland's drug regulator banned GSK from stating on its patient information leaflet that paroxetine „works by bringing serotonin levels back to normal.” Officials stated that „There is no scientific investigation to measure what are normal serotonin levels in the human brain receptors. As such, claiming that a particular medicinal product works by bringing serotonin levels back to normal is not accurate.”

The claims do not appear on Canadian product information, says Health Canada spokesperson Chris Williams. The Paxil monograph states it is „thought to work by increasing levels of serotonin in the brain.”

Goodman would not comment on whether the FDA should ban these claims. While he accepts that claiming SSRIs correct a serotonin imbalance goes „too far,” he says he has no problem if patients are told that SSRIs normalize some kind of chemical imbalance or disturbance. „I think that is reasonable shorthand for expressing that this is a chemically or brain-based problem and that the medications are normalizing function.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (6)
CMAJ
Vol. 174, Issue 6
14 Mar 2006
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SSRI ads questioned
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SSRI ads questioned
Colin Meek
CMAJ Mar 2006, 174 (6) 754-754-a; DOI: 10.1503/cmaj.051634

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
SSRI ads questioned
Colin Meek
CMAJ Mar 2006, 174 (6) 754-754-a; DOI: 10.1503/cmaj.051634
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Unpacking “long COVID”
  • Health advocates want help handling online harassment
  • Canada’s long road to a vaccine injury compensation program
Show more News

Similar Articles

Collections

  • Topics
    • Drugs: psychotherapeutic
    • Drug regulation

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire